Rakuten Investment Management’s Royalty Pharma RPRX Stock Holding History

Rakuten Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$327K	Buy	+10,420	New	+$330K	﹤0.01%	617

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rakuten Investment Management's RPRX Position: Q1 2025 in Review

Rakuten Investment Management opened a new position in Royalty Pharma (RPRX) in Q1 2025: 10,420 shares worth $327K. The stake represents ﹤0.01% of the portfolio and ranks #617 among its holdings.

447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

Rakuten Investment Management held 10,420 shares of Royalty Pharma worth $327K as of Q1 2025.
Royalty Pharma was a new Rakuten Investment Management position in Q1 2025.
Royalty Pharma made up ﹤0.01% of Rakuten Investment Management's portfolio in Q1 2025, its #617 holding.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Rakuten Investment Management's 13F filing for Q1 2025, filed 15 May 2025.